title: Platycodin D Attenuates Airway Inflammation in a Mouse Model of Allergic Asthma by Regulation NF-κB Pathway.
abstract: In this work, the anti-asthma potential of platycodin D (PLD) was studied by investigation of its effect to suppress airway inflammation, a murine model of asthma and the possible mechanisms. A total of 50 mice were randomly assigned to five experimental groups: control, ovalbumin (OVA), OVA+dexamethasone (2 mg/kg) and OVA+PLD (40, 80 mg/kg). Airway resistance (Raw) were measured; airway histological studies were evaluated by the hematoxylin and eosin (HE) staining; interleukin-4 (IL-4), interleukin-5(IL-5), and interleukin-13 in bronchoalveolar lavage fluid (BALF) were evaluated by enzyme-linked immunosorbent assay (ELISA); NF-κBp65, p-NF-κBp65, p-IKKα, IKKα, p-IKKβ, p-IкBα, and IкBα of airway were measured by Western blotting. Our study demonstrated that PLD inhibited OVA-induced increases in Raw and eosinophil count in airway; IL-4, IL-5, and IL-13 were recovered in BALF. Histological studies demonstrated that PLD substantially inhibited OVA-induced eosinophilia in airway tissue. Western blotting studies demonstrated that PLD substantially inhibited NF-κB pathway. These findings suggest that PLD may effectively ameliorate the progression of asthma and could be used as a therapy for patients with allergic asthma.
authors.affiliation: Changchun University of Chinese Medicine, Changhcun, 130117, China.
authors.forename: Tianzhu
authors.initials: T
authors.lastname: Zhang
authors.forename: Shihai
authors.initials: S
authors.lastname: Yang
authors.forename: Juan
authors.initials: J
authors.lastname: Du
authors.forename: Yao
authors.initials: Y
authors.lastname: Jinfu
authors.forename: Wang
authors.initials: W
authors.lastname: Shumin
mesh_terms: D000403:Airway Resistance / Q000187:drug effects*; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D029422:Campanulaceae / Q000378:metabolism; D003907:Dexamethasone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004802:Eosinophilia / Q000188:drug therapy; D004804:Eosinophils / Q000276:immunology; D005260:Female; D051550:I-kappa B Kinase / Q000378:metabolism; D020672:I-kappa B Proteins / Q000378:metabolism; D018793:Interleukin-13 / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D015848:Interleukin-5 / Q000378:metabolism; D008168:Lung / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D000072000:NF-KappaB Inhibitor alpha; D010047:Ovalbumin; D010936:Plant Extracts / Q000627:therapeutic use; D011897:Random Allocation; D012503:Saponins / Q000627:therapeutic use*; D051996:Transcription Factor RelA / Q000378:metabolism; D014315:Triterpenes / Q000627:therapeutic use*
chemical_list: D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D020672:I-kappa B Proteins; D018793:Interleukin-13; D015848:Interleukin-5; C000606205:Nfkbia protein, mouse; D010936:Plant Extracts; C498144:Rela protein, mouse; D012503:Saponins; D051996:Transcription Factor RelA; D014315:Triterpenes; D000072000:NF-KappaB Inhibitor alpha; D015847:Interleukin-4; D003907:Dexamethasone; D010047:Ovalbumin; C108953:platycodin D; D051550:I-kappa B Kinase